Business Wire·Nov 10, 2026, 8:00 AM ET

Omniose Announces Its Acquisition by AstraZeneca

AstraZeneca has acquired Omniose, a preclinical biotechnology company, making it a wholly owned subsidiary within its Infectious Disease Unit.
The acquisition follows a three-year exclusive research collaboration between the two organizations.
Omniose's proprietary bioconjugation platform complements AstraZeneca's existing capabilities in bacterial vaccines & preclinical programs.
Unlike traditional chemical processes, Omniose's approach links bacterial polysaccharides & carrier proteins within a single cell using enzymatic methods.
This single-cell bioconjugation method offers a simpler manufacturing process & enables more precise molecular design for higher-quality vaccines.
The deal aims to advance novel vaccine development against serious bacterial infections complicated by antimicrobial resistance.
Christian Harding, Omniose's CSO, stated the acquisition provides the best opportunity for their platform to reach patients.
Benjamin Moutier of AstraZeneca noted the technology strengthens their ability to engineer conjugate vaccines against serious bacterial threats.
Timothy Cooke, Omniose's CEO, described the acquisition as a great outcome for both organizations sharing a vision to address bacterial infections.
Omniose utilizes engineered E. coli cells to simultaneously produce antigens, carrier proteins, & conjugating enzymes for precise attachment.